<DOC>
	<DOCNO>NCT00651287</DOCNO>
	<brief_summary>The purpose study determine response rate therapeutic goal ( diastolic blood pressure ( BP ) less 90 mmHg systolic BP le 140 mmHg ) Week 6 quinapril 20 mg Week 12 quinapril 20 mg , quinapril 40 mg , quinapril 20 mg plus hydrochlorothiazide 12.5 mg ; determine mean decrease diastolic systolic BP measurement change heart rate Week 6 Week 12 compare baseline .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Quinapril Quinapril Plus Hydrochlorothiazide Patients With Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Quinapril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>A clinical diagnosis mild moderate primary hypertension ( `` Joint National Committee Prevention , Detection , Evaluation , Treatment High Blood Pressure , 6th report '' Stage I II ) Sitting diastolic blood pressure 90 mmHg 109 mmHg systolic blood pressure 140 mmHg 179 mmHg end notreatment runin period Subjects secondary hypertension Subjects serious cardiac disease ( include myocardial infarction last 3 month decompensated heart failure ) Subjects accept stop use antihypertensive treatment runin period treatment period study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>